Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label subcutaneous sibeprenlimab study in IgA nephropathy
CTR20253951Phase 3Active
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sibeprenlimab in IgA nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20253951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253951.